Rivermed Sp. z o.o.

Poznan 15 trials 5 recruiting

15 Registered trials

5 Currently recruiting

Organisation

Rivermed Sp. z o.o.

Location

Poznan, Poland

Identifier

ORG-100047198

Address

Ul. 28 Czerwca 1956 R. Nr 382/u4, 61-441, Poland

Departments

Gabinety Lekarskie Rivermed
N/A
NA
Neurology
PL10019: Gabinety Lekarskie RIVERMED
PL10035: Gabinety Lekarskie RIVERMED

Clinical trials at this site (15)

Search interface

A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn'… Recruiting

2024-513054-30-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011) Recruiting

2024-513533-20-00 Crohn’s Disease or Ulcerative Colitis 5 2025-02-25
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended

2024-518998-33-00 Ulcerative Colitis 5 2025-07-23
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat… Ended

2024-513015-27-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2025-01-09
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended

2023-505635-13-00 Systemic lupus erythematosus 5 2022-06-10
A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin… Ended

2023-505695-30-00 systemic lupus erythematosus 5 2021-11-30
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended

2023-506655-19-00 Ulcerative Colitis (UC) 4 2024-05-16
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended

2022-503005-38-00 Ulcerative Colitis 4 2023-12-04
A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended

2024-515177-94-00 Parkinson's Disease 4 2023-06-21
A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended

2023-509741-12-00 Ulcerative Colitis 4 2021-09-23